From genome integrity to cancer by Nik-Zainal, Serena
EDITORIAL Open Access
From genome integrity to cancer
Serena Nik-Zainal1,2
The genome in each of our normal cells acquires somatic
genetic changes throughout life [1]. The burden of DNA
damage from exogenous and endogenous sources is con-
siderable, but highly competent DNA repair pathways op-
erate in concert to maintain genome integrity [1].
By contrast, the genomes of cancerous cells are a
source of biological information regarding cancer devel-
opment, identifying DNA repair pathways that have
gone awry and unveiling excessive DNA damage from
external sources [1–3]. They may even serve as a record
of physiological processes that are acting inappropriately
(e.g., replication stress) [4, 5]. These genomes provide a
read-out of the pathological processes that operate in
cells as they transition from normality towards malig-
nancy. The read-out can be seen as patterns of muta-
tions, or mutational signatures, at the single nucleotide
variant (SNV) level [1–3], as insertions/deletions
(indels), as structural variation [4, 5], and even as
chromosomal copy number changes [4, 5]. It can mani-
fest as physical abnormalities such as the presence of
micronuclei. In other words, outcomes can be appreci-
ated across a whole spectrum of resolutions, ranging
from base-pair changes to alterations on the chromo-
somal scale [5]. The loss of genome integrity is thus
highly informative [6], revealing why a tumor has
formed and, crucially, how we can potentially exploit
these processes in interventions.
This special issue of Genome Medicine highlights the
advances made in understanding how compromised gen-
ome integrity impacts genome architecture, tumor biol-
ogy, immune escape, and the mechanisms underlying
differential response and resistance to cancer therapies,
outlining new avenues for precision therapies and
clinical decision-making. For example, at base pair
resolution, a high frequency of SNVs with characteristic
C > A and T > C mutations, together with a high degree
of indel formation at polynucleotide repeat tracts (also
termed microsatellite instability), has been found in
tumors with mismatch repair deficiencies (MMRd) [7].
It is important to detect tumors that have MMRd be-
cause of their reported sensitivities to immunotherapy
[8, 9], regardless of the cell of origin. Tumors with alter-
native, distinctive C > A, C > T, and T > G mutations that
are associated with activating mutations in the DNA
polymerase epsilon gene (POLE) have also been sug-
gested to be sensitive to checkpoint inhibitors [10, 11].
These examples of nucleotide-resolution genomic in-
stability contrast with those associated with germline de-
ficiencies in the genes of the homology-directed repair
(HR) pathway, such as BRCA1 and BRCA2 [2, 4, 12]. In
patients with BRCA1/BRCA2 deficiencies, mutational
patterns at the SNV and indel levels are reported in con-
junction with structural variations and changes at the
chromosomal copy number level [4, 12]. Thus, the loss
of genome integrity occurs at all levels of genomic reso-
lution in HR-deficient tumors. These pathognomonic
patterns of genomic instability have been exploited; for
example, algorithms have been developed to identify
sporadic tumors with BRCA1/BRCA2 phenotypes in pa-
tients who are not germline BRCA1/BRCA2 mutation
carriers [12]. Intriguingly, these efforts revealed that the
proportion of tumors that have acquired such deficien-
cies is much larger than was previously appreciated. This
is significant because it means that patterns of genomic
instability can be used as biomarkers to identify
additional tumors that are potentially sensitive to thera-
peutics originally designed for germline BRCA1/BRCA2-
deficient tumors, such as poly (ADP-ribose) polymerase
(PARP) inhibitors. Furthermore, these tumors need not
be restricted to breast and ovarian cancers and could in-
volve other cancer types too.
The loss of genomic integrity can be influenced by
a variety of additional physiological processes, such as
transcription and replication [13], the formation of
R-loops [14–16], and epigenomic dysregulation [17].
In due course, these additional layers of genomic in-
formation will be added to the mix, informing our
understanding of the burden and distribution of mu-
tagenesis and of how we can exploit this new know-
ledge for patient benefit.
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A critical feature of cells that have on-going genomic
instability is the higher likelihood that new and poten-
tially therapy-resistant clones will be generated. In this
special issue, we read how loss of Jun promotes resist-
ance to the histone deacetylase inhibitor entinostat in lu-
minal breast cancer through Myc signaling. Entinostat is
in phase III trials for patients with metastatic
estrogen-receptor-positive breast cancer, and thus Jun
and MYC may represent biomarkers of entinostat re-
sponsiveness in breast cancer [18]. Evolvability can arise
through the disruption of critical genes or pathways, or
through the development of properties that permit cells
to escape immune-surveillance [19] and thus promote
immune evasion. This area of research has already
shown considerable promise, and much work has gone
into exploring genomic instability and how it affects
evolvability following therapeutic intervention [20, 21].
One area that remains poorly studied is whether there
are patterns of genomic instability that distinguish nor-
mal cells from cancer cells. Until recently, much of the
analysis of mutational patterns has been focused on can-
cers that have arisen from some common ancestor and
thus are clonal in origin. The ability to study the gen-
omic integrity of single cells has been restricted to copy
number variation because of the limitations of the rele-
vant technology. In due course, patterns of genomic in-
stability that are perfectly well tolerated in normal cells
may be revealed. By contrast, there may be typical forms
of loss of genomic integrity that are associated with ma-
lignancy or even with poor treatment response and
prognosis outcome.
Finally, to tolerate the high burden of mutagenesis,
tumors have developed intrinsic properties that per-
mit enduring survival, which are undoubtedly molded
by the tumor microenvironment and the patient’s im-
mune response [22]. Human cancers may thus be
addicted to features such as checkpoint bypass or
may be dependent on alternative components of DNA
repair for their survival. These features, however,
make cancer cells selectively targetable for therapeutic
intervention. The principle of synthetic lethality is
predicated on this very point: tumor cells that are
null for error-free HR repair are wholly dependent on
alternative ways of fixing single-strand breaks. PARP
inhibition exploits this point, so that tumor cells are
selectively sensitive to PARP-inhibiting drugs and
consequently better tolerated in patients. Other
synthetic lethality relationships may well exist and
remain to be discovered and exploited for the devel-
opment of new drugs. Using synthetic lethality
screening, Bernards and colleagues [23] show that the
unfolded protein response pathway may serve as a
new potential target for drug-resistant KRAS-mutant
colorectal cancers.
The loss of genome integrity, if producing a character-
istic pattern, could be used as a marker for prognosis or
as a read-out for the stratification of cancer patients. In
fact, such patterns could be used even in the absence of
an identified genetic or epigenetic driver. In other words,
using patterns of loss of genomic integrity could serve as
an additional tool in the tool box of diagnostic clinical
genomics. We can look forward to a future when a pa-
tient’s treatment will be informed by the biological ab-
normalities that are present in their tumor, based on the
general patterns of loss of genomic integrity and not
simply on a binary decision of whether a driver mutation
is present or not. The profiling of circulating tumor
DNA (ctDNA) is becoming increasingly important in
clinical oncology, with ctDNA profiling methods being
developed and applied in the patient setting for monitor-
ing disease [24] and for capturing the landscape of meta-
static disease [25].
When we have gained a deeper understanding of the
factors that are required to maintain genomic integrity
and have developed greater insights into the causes and
consequences of genomic instability, and of course have
validated these ideas within clinical trials, perhaps com-
prehensive genomics will become an imperceptible part
of every patient’s diagnostic work-up. Like routine blood
screening, a staging computed tomography (CT) scan,
or a positron emission tomography (PET) scan, genom-
ics could become an accepted (and even necessary)
screening tool that informs patient care.
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